CEBPA and acute myeloid leukemia: In contrast to this, a block of miR-182 expression by either lentiviral expression of a decoy-miR-182 vector in leukemic U937 and Kasumi-1 cells or by treatment of primary AML patient cells with therapeutic dosages of locked nucleic acids (LNAs) against miR-182 resulted in elevated C/EBPα protein levels (Fig. 4e).